Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 745

1.

Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.

Przepiorka D, Buadi FK, McClune B.

Pharmacotherapy. 2008 Jan;28(1):58-63.

PMID:
18154475
2.

Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.

Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP.

Pharmacotherapy. 2007 Jul;27(7):970-9.

3.

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.

Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR.

Pediatr Infect Dis J. 2002 Mar;21(3):240-8.

PMID:
12005089
4.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
5.

A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).

Vehreschild JJ, Böhme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, Drzisga I, Cornely OA.

J Infect. 2007 Nov;55(5):445-9. Epub 2007 Sep 6.

PMID:
17822770
6.

Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole.

Vehreschild JJ, Böhme A, Reichert D, Kiehl MG, Arenz D, Pankraz K, Kochanek M, Ullmann AJ, Cornely OA.

Int J Hematol. 2008 Mar;87(2):126-31. doi: 10.1007/s12185-008-0045-z. Epub 2008 Feb 21.

7.

Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.

den Hollander JG, van Arkel C, Rijnders BJ, Lugtenburg PJ, de Marie S, Levin MD.

J Antimicrob Chemother. 2006 Jun;57(6):1248-50. Epub 2006 Mar 23.

PMID:
16556632
8.

Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.

Collins CD, Stuntebeck ER, DePestel DD, Stevenson JG.

Clin Drug Investig. 2007;27(4):233-41.

PMID:
17358095
9.

Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.

Marty FM, Lowry CM, Cutler CS, Campbell BJ, Fiumara K, Baden LR, Antin JH.

Biol Blood Marrow Transplant. 2006 May;12(5):552-9.

10.
11.

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.

Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K; Itraconazole Neutropenia Study Group.

Ann Intern Med. 2001 Sep 18;135(6):412-22.

PMID:
11560454
12.

Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.

Fournier S, Pavageau W, Feuillhade M, Deplus S, Zagdanski AM, Verola O, Dombret H, Molina JM.

Eur J Clin Microbiol Infect Dis. 2002 Dec;21(12):892-6. Epub 2002 Nov 1. Review.

PMID:
12525928
13.

Voriconazole : a review of its use in the management of invasive fungal infections.

Scott LJ, Simpson D.

Drugs. 2007;67(2):269-98. Review.

PMID:
17284090
14.

A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.

Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC.

Am J Med. 2000 Mar;108(4):282-9.

PMID:
11014720
15.

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhédin N, Isnard F, Ades L, Kuhnowski F, Foulet F, Kuentz M, Maison P, Bretagne S, Schwarzinger M.

Clin Infect Dis. 2009 Apr 15;48(8):1042-51. doi: 10.1086/597395.

PMID:
19281327
16.

Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.

[No authors listed]

Prescrire Int. 2004 Feb;13(69):13-6.

PMID:
15055210
17.

Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study.

Maschmeyer G, Heinz WJ, Hertenstein B, Horst HA, Requadt C, Wagner T, Cornely OA, Löffler J, Ruhnke M; IDEA study investigators.

Eur J Clin Microbiol Infect Dis. 2013 May;32(5):679-89. doi: 10.1007/s10096-012-1794-4. Epub 2012 Dec 28.

PMID:
23271674
18.

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J; National Institute of Allergy and Infectious Diseases Mycoses Study Group.

N Engl J Med. 2002 Jan 24;346(4):225-34. Erratum in: N Engl J Med. 2007 Feb 15;356(7):760.

19.

Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia.

Yu DT, Seger DL, Peterson JF, Kumar RN, Bates DW.

BMC Infect Dis. 2006 Dec 5;6:173.

20.

Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.

Al-Badriyeh D, Liew D, Stewart K, Kong DC.

J Antimicrob Chemother. 2009 Jan;63(1):197-208. doi: 10.1093/jac/dkn459. Epub 2008 Nov 11.

PMID:
19001450

Supplemental Content

Support Center